Microbiological Research, Journal Year: 2024, Volume and Issue: 291, P. 127982 - 127982
Published: Nov. 22, 2024
Language: Английский
Biotechnology Advances, Journal Year: 2025, Volume and Issue: unknown, P. 108570 - 108570
Published: March 1, 2025
This review provides a comprehensive analysis of antimicrobial peptides (AMPs), exploring their diverse sources, secondary structures, and unique characteristics. The explores into the mechanisms underlying antibacterial, immunomodulatory effects, antiviral, antiparasitic antitumour AMPs. Furthermore, it discusses three principal synthesis pathways for AMPs assesses current clinical applications preclinical research status. paper also addresses limitations AMPs, including issues related to stability, resistance, toxicity, while offering insights strategies enhancement. Recent advancements in AMP research, such as chemical modifications (including amino acid sequence optimisation, terminal side-chain modifications, PEGylation, conjugation with small molecules, photosensitisers, metal ligands, polymerisation, cyclisation specifically targeted peptides) are highlighted. goal is provide foundation future design optimisation
Language: Английский
Citations
1
Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 15
Published: April 28, 2025
Antimicrobial peptides (AMPs) are critical effectors of innate immunity, presenting a compelling alternative to conventional antibiotics amidst escalating antimicrobial resistance. Their broad-spectrum efficacy and inherent low resistance development countered by production challenges, including limited yields proteolytic degradation, which restrict their clinical translation. While chemical synthesis offers precise structural control, it is often prohibitively expensive complex for large-scale production. Heterologous expression systems provide scalable, cost-effective platform, but necessitate optimization. This review comprehensively examines established emerging AMP strategies, encompassing fusion protein technologies, molecular engineering approaches, rational peptide design, post-translational modifications, with an emphasis on maximizing yield, bioactivity, stability, safety. Furthermore, we underscore the transformative role artificial intelligence, particularly machine learning algorithms, in accelerating discovery optimization, thereby propelling expanded therapeutic application contributing global fight against drug-resistant infections.
Language: Английский
Citations
0
Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(5), P. 679 - 679
Published: May 2, 2025
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a multidrug-resistant (MDR) gram-negative bacterium frequently involved in hospital-acquired pneumonia. The infection caused by this superbug has spread quickly health centers worldwide, leading to high mortality rates. Due emerging scenario, the World Health Organization categorized CRKP as highest-priority species for development of new compounds. In context, antimicrobial peptides (AMPs) stand out prototypes alternative antimicrobials against superbugs, including CRKP. Objectives: We aimed describe antibacterial effect an AMP (LyeTx I), derived from venom spider Lycosa erythrognatha, vitro and murine pneumonia model. Results: LyeTx I showed effects all clinical isolates tested, with minimum inhibitory concentration (MIC) range 2–8 µM bactericidal (MBC) 2–16 µM. microbial anionic membrane was primary target I, which acts displacing divalent cations bound structure manner similar that polymyxins. Notably, displayed significant lytic activity mimetic membranes, indicating its potential disrupt bacterial cell integrity. vivo assays, peptide proved be safe at dose 10 mg/kg. addition, intraperitoneal use reduced load inflammation lungs animals infected hypervirulent strain Conclusions: These results indicate prototype antibacterials MDR species, such
Language: Английский
Citations
0
The Science of The Total Environment, Journal Year: 2025, Volume and Issue: 982, P. 179641 - 179641
Published: May 14, 2025
Language: Английский
Citations
0
BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)
Published: May 21, 2025
Bloodstream infection (BSI) caused by carbapenem-resistant Enterobacterales (CRE) is a major global public health concern due to its high lethality and limited treatment options. In Brazil, CRE was first reported in 2005, with Klebsiella pneumoniae carbapenemase (KPC) documented 2009. Despite ongoing reports, data remain several regions. To describe the rate epidemiological clinical characteristics of BSI patients assess carbapenem resistance identify risk factors for lethality. This prospective laboratory-based surveillance study, which conducted two tertiary hospitals (April 2016-December 2018), analyzed cases Enterobacterales. Clinical demographic were obtained from medical records. The bacterial isolates identified mass spectrometry VITEK-2®, antimicrobial susceptibility testing performed VITEK-2®. Logistic regression Kaplan‒Meier survival analyses used impact on death. Among 252 enterobacterial BSIs identified, 14.3% had CRE. overall 37.7%. Compared carbapenem-susceptible Enterobacterales, CRE-associated associated significantly greater (71.6% vs. 28.4%; p < 0.001; OR = 6.53, 95% CI [3.01-15.41]). association remained significant after adjusting age, comorbidities, Pitt bacteremia score, species, type, sepsis. All hospital-acquired. accounts strongly increased Given this study provides valuable insights that may inform local protocols infections.
Language: Английский
Citations
0
Infection and Drug Resistance, Journal Year: 2024, Volume and Issue: Volume 17, P. 3723 - 3735
Published: Aug. 1, 2024
complex (ECC), which includes major nosocomial pathogens, causes urinary, respiratory, and bloodstream infections in humans, for colistin is one of the last-line drugs.
Language: Английский
Citations
2
Pathogens, Journal Year: 2024, Volume and Issue: 13(12), P. 1049 - 1049
Published: Nov. 28, 2024
The emergence of antibiotic-resistant Acinetobacter baumannii (A. baumannii) is a pressing threat in clinical settings. Colistin currently widely used treatment for multidrug-resistant A. baumannii, serving as the last line defense. However, reports colistin-resistant strains have emerged, underscoring urgent need to develop alternative medications combat these serious pathogens. To resist colistin, has developed several mechanisms. These include loss outer membrane lipopolysaccharides (LPSs) due mutation LPS biosynthetic genes, modification lipid A (a constituent LPSs) structure through addition phosphoethanolamine (PEtN) moieties component by overexpression chromosomal pmrCAB operon genes and eptA gene, or acquisition plasmid-encoded mcr horizontal gene transfer. Other resistance mechanisms involve alterations permeability porins, expulsion colistin efflux pumps, heteroresistance. In response rising researchers various strategies, including antibiotic combination therapy, adjuvants potentiate activity, repurposing existing drugs, antimicrobial peptides, nanotechnology, photodynamic CRISPR/Cas, phage therapy. While many strategies shown promise vitro vivo, further trials are necessary ensure their efficacy widen applications. Ongoing research essential identifying most effective therapeutic manage baumannii. This review explores genetic underlying assesses potential options this challenging pathogen.
Language: Английский
Citations
1
Pathogens, Journal Year: 2024, Volume and Issue: 13(11), P. 921 - 921
Published: Oct. 22, 2024
Polymyxin antibiotics B and colistin are considered drugs of last resort for the treatment multi-drug carbapenem-resistant Gram-negative bacteria. With emergence dissemination resistance, monitoring use resistance to polymyxins imparted by mobilised genes (
Language: Английский
Citations
0
Microbiological Research, Journal Year: 2024, Volume and Issue: 291, P. 127982 - 127982
Published: Nov. 22, 2024
Language: Английский
Citations
0